Jcr Pharmaceuticals
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 32 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2021, JCR Pharmaceuticals reported total carbon emissions of approximately 85,536,000 kg CO2e. This figure includes Scope 1 emissions of about 2,232,000 kg CO2e, Scope 2 emissions of approximately 5,136,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 78,168,000 kg CO2e. The Scope 3 emissions breakdown reveals that purchased goods and services accounted for the largest share, at about 70,232,000 kg CO2e. JCR Pharmaceuticals is committed to addressing climate change by aligning its strategies with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD). The company has set near-term reduction targets for both Scope 1 and Scope 2 emissions, aiming to enhance its greenhouse gas (GHG) emissions analysis and disclosure from 2023 to 2025. While specific percentage reduction targets have not been disclosed, the focus on comprehensive GHG emissions calculation across its entire supply chain indicates a proactive approach to sustainability. Overall, JCR Pharmaceuticals is taking significant steps towards understanding and mitigating its carbon footprint, reflecting a commitment to climate responsibility in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 2,232,000 |
| Scope 2 | 5,136,000 |
| Scope 3 | 78,168,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jcr Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
